<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834886</url>
  </required_header>
  <id_info>
    <org_study_id>00834886</org_study_id>
    <nct_id>NCT00834886</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial on the Treatment Effects of Melatonin and Light Therapy on Delayed Sleep Phase Syndrome</brief_title>
  <official_title>Delayed Sleep Phase Syndrome in Adolescents and Young Adults. Sleep, Personality, Developmental History, Circadian Rhythm, Daytime Functioning and Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bergen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will examine the effects of melatonin and light therapy on
      delayed sleep phase syndrome in adolescents 16 up to 20 years old. 60 subjects will be
      randomized into four different groups; melatonin + light therapy (N=15), melatonin + placebo
      light (N=15), placebo + light therapy (N=15) and placebo + placebo light. This is a
      double-blinded treatment and the participants will receive this treatment for 2 weeks. Then
      they will be re-randomized into two groups; full treatment with light therapy + melatonin
      (N=30) and no treatment (N=30) for 3 months unblinded. The investigators will test the
      subjects pre-treatment, post 2 week treatment and after 3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delayed sleep phase syndrome (DSPS) is a circadian rhythm sleep disorder where the sleep-wake
      rhythm is significantly delayed according to the environmental demands. Hence, the symptoms
      consist of major difficulties falling asleep and problems awakening in due time and patients
      often experience work- and school related impairments (The International Classification of
      Sleep Disorders: Diagnostic and Coding manual, 2005). However, correct diagnosis is often not
      made and the treatment offered is, accordingly, often inadequate. DSPS normally develops in
      interplay between dysfunctional habits/behaviour and biological vulnerability.

      Bright light therapy and administration of exogenous melatonin comprise the most common
      interventions. Timed bright light has been shown to effectively phase advance the rhythm
      (Rosenthal et al., 1990), but no standardized guidelines regarding the duration, intensity or
      timing of light exposure have been established. Compliance to the treatment is often poor
      because it involves structuring the daily schedule, which may be hard for the relevant age
      group. Similarly, administration of melatonin in the evening has been shown to phase advance
      the rhythm (Lewy et al., 1998; Mundey, Benloucif, Harsanyi, Dubocovich, &amp; Zee, 2005), but a
      standardized approach for dose, duration and timing is lacking.

      It is important to establish effective treatment guidelines for delayed sleep phase syndrome.
      Large scale studies on the effects of melatonin and bright light treatment in randomized
      placebo-controlled designs are needed. In a clinical trial we aim to investigate the efficacy
      of bright light and melatonin treatment using a 4 armed randomized placebo controlled design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Investigate the Efficacy on Rise Time of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log, Actigraphy and Psychological Tests.</measure>
    <time_frame>1 day after two-week treatment ends</time_frame>
    <description>Sleep diary, rise time (when participants rise from bed in the morning, self-report) before and after a randomized controlled 4 armed treatment study including a follow-up 3 months later.
Midnight is 0000; in the outcome measure table the value is given in minutes after midnight.
i.e. 530 equals 08:50 in the morning.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Investigate the Efficacy on Subjective Sleepiness of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log, Actigraphy and Psychological Tests.</measure>
    <time_frame>1 day after 2-week treatment ended</time_frame>
    <description>Subjective sleepiness; Karolinska sleepiness scale (KSS). The KSS is a scale in which the subjects rate their concurrent sleepiness level. The scale is verbally anchored with steps ranging from 1 (&quot;very alert&quot;) to 9 (&quot;very sleepy, fighting sleep, effort to stay awake&quot;).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Investigate the Efficacy on Sleep Onsel Latency of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log, Actigraphy and Psychological Tests.</measure>
    <time_frame>1 day after 2-week treatment ended</time_frame>
    <description>Actigraphy, sleep onset latency (SOL). An actigraph is a wrist-worn movement sensor that objectively record motor activity. Participants used an event button to mark bed time and rise time. The actiwatch is waterproof and participants were instructed not to take it off at any time during the data collection peroid.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Delayed Sleep Phase Syndrome</condition>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bright light 10.000 lux + melatonin 3 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melatonin 3 mg + placebo red light 400 lux</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bright light</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bright light 10.000 lux + placebo capsule 3 mg rice flour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Red light 400 lux + placebo capsule 3 mg rice flour</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Capsules, 3 mg, once every night</description>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_label>Melatonin</arm_group_label>
    <other_name>Nature´s One melatonin, by Asman, Inc.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bright light</intervention_name>
    <description>Bright light therapy 10.000 lux by Miljølys AS</description>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_label>Bright light</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo red light</intervention_name>
    <description>Red light 400 lux as placebo light</description>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Capsules containing 3 mng rice flour, once every night</description>
    <arm_group_label>Bright light</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  16-25 years old

          -  lives in the Bergen area

          -  has Delayed Sleep Phase Disorder

        Exclusion Criteria:

          -  pregnant or nursing women

          -  other sleep disorders (i.e. sleep apnoea or PLMS)

          -  moderate to serious psychiatric disease

          -  use of psychopharmacological medicines

          -  in psychotherapeutic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjørn Bjorvatn, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bergen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bergen</name>
      <address>
        <city>Bergen</city>
        <zip>5020</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Wilhelmsen-Langeland A, Saxvig IW, Pallesen S, Nordhus IH, Vedaa Ø, Lundervold AJ, Bjorvatn B. A randomized controlled trial with bright light and melatonin for the treatment of delayed sleep phase disorder: effects on subjective and objective sleepiness and cognitive function. J Biol Rhythms. 2013 Oct;28(5):306-21. doi: 10.1177/0748730413500126.</citation>
    <PMID>24132057</PMID>
  </results_reference>
  <results_reference>
    <citation>Saxvig IW, Wilhelmsen-Langeland A, Pallesen S, Vedaa O, Nordhus IH, Bjorvatn B. A randomized controlled trial with bright light and melatonin for delayed sleep phase disorder: effects on subjective and objective sleep. Chronobiol Int. 2014 Feb;31(1):72-86. doi: 10.3109/07420528.2013.823200. Epub 2013 Oct 21.</citation>
    <PMID>24144243</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>August 1, 2014</results_first_submitted>
  <results_first_submitted_qc>December 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2014</results_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bergen</investigator_affiliation>
    <investigator_full_name>Bjorn Bjorvatn</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sleep Disorders, Circadian Rhythm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Publications from the stury are reported here. IPD can be retrieved upon request to the study investigator.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combination</title>
          <description>Melatonin: Capsules, 3 mg, once every night
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
        </group>
        <group group_id="P2">
          <title>Melatonin</title>
          <description>Melatonin: Capsules, 3 mg, once every night
placebo light therapy: Placebo light</description>
        </group>
        <group group_id="P3">
          <title>Bright Light</title>
          <description>Placebo melatonin: Capsule 3 mg, rice flour
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo melatonin + placebo light therapy
Placebo melatonin: Capsule 3 mg, rice flour
placebo light therapy: Placebo light</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melatonin and Light Therapy</title>
          <description>Melatonin: Capsules, 3 mg, once every night
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
        </group>
        <group group_id="B2">
          <title>Melatonin and Placebo Light</title>
          <description>Melatonin: Capsules, 3 mg, once every night
placebo light therapy: Placebo light</description>
        </group>
        <group group_id="B3">
          <title>Placebo Melatonin and Light Therapy</title>
          <description>Placebo melatonin: Capsule 3 mg, rice flour
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
        </group>
        <group group_id="B4">
          <title>Placebo Melatonin and Placebo Light</title>
          <description>Placebo melatonin + placebo light therapy
Placebo melatonin: Capsule 3 mg, rice flour
placebo light therapy: Placebo light</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.3" spread="3.3"/>
                    <measurement group_id="B2" value="21.2" spread="2.7"/>
                    <measurement group_id="B3" value="20.7" spread="3.4"/>
                    <measurement group_id="B4" value="20.8" spread="3.4"/>
                    <measurement group_id="B5" value="20.7" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Investigate the Efficacy on Rise Time of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log, Actigraphy and Psychological Tests.</title>
        <description>Sleep diary, rise time (when participants rise from bed in the morning, self-report) before and after a randomized controlled 4 armed treatment study including a follow-up 3 months later.
Midnight is 0000; in the outcome measure table the value is given in minutes after midnight.
i.e. 530 equals 08:50 in the morning.</description>
        <time_frame>1 day after two-week treatment ends</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination</title>
            <description>Bright light + melatonin
Melatonin: Capsules, 3 mg, once every night
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
          </group>
          <group group_id="O2">
            <title>Melatonin</title>
            <description>Melatonin + placebo light
Melatonin: Capsules, 3 mg, once every night
placebo light therapy: Placebo light</description>
          </group>
          <group group_id="O3">
            <title>Bright Light</title>
            <description>Bright light + placebo capsule
Placebo melatonin: Capsule 3 mg, rice flour
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo capsule + placebo light
Placebo melatonin: Capsule 3 mg, rice flour
placebo light therapy: Placebo light</description>
          </group>
        </group_list>
        <measure>
          <title>To Investigate the Efficacy on Rise Time of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log, Actigraphy and Psychological Tests.</title>
          <description>Sleep diary, rise time (when participants rise from bed in the morning, self-report) before and after a randomized controlled 4 armed treatment study including a follow-up 3 months later.
Midnight is 0000; in the outcome measure table the value is given in minutes after midnight.
i.e. 530 equals 08:50 in the morning.</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="530" spread="121"/>
                    <measurement group_id="O2" value="506" spread="98"/>
                    <measurement group_id="O3" value="520" spread="148"/>
                    <measurement group_id="O4" value="543" spread="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Investigate the Efficacy on Subjective Sleepiness of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log, Actigraphy and Psychological Tests.</title>
        <description>Subjective sleepiness; Karolinska sleepiness scale (KSS). The KSS is a scale in which the subjects rate their concurrent sleepiness level. The scale is verbally anchored with steps ranging from 1 (&quot;very alert&quot;) to 9 (&quot;very sleepy, fighting sleep, effort to stay awake&quot;).</description>
        <time_frame>1 day after 2-week treatment ended</time_frame>
        <population>All participants in the four arms</population>
        <group_list>
          <group group_id="O1">
            <title>Combination</title>
            <description>Bright light + melatonin
Melatonin: Capsules, 3 mg, once every night
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
          </group>
          <group group_id="O2">
            <title>Melatonin</title>
            <description>Melatonin + placebo light
Melatonin: Capsules, 3 mg, once every night
placebo light therapy: Placebo light</description>
          </group>
          <group group_id="O3">
            <title>Bright Light</title>
            <description>Bright light + placebo capsule
Placebo melatonin: Capsule 3 mg, rice flour
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo capsule + placebo light
Placebo melatonin: Capsule 3 mg, rice flour
placebo light therapy: Placebo light</description>
          </group>
        </group_list>
        <measure>
          <title>To Investigate the Efficacy on Subjective Sleepiness of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log, Actigraphy and Psychological Tests.</title>
          <description>Subjective sleepiness; Karolinska sleepiness scale (KSS). The KSS is a scale in which the subjects rate their concurrent sleepiness level. The scale is verbally anchored with steps ranging from 1 (&quot;very alert&quot;) to 9 (&quot;very sleepy, fighting sleep, effort to stay awake&quot;).</description>
          <population>All participants in the four arms</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="1.6"/>
                    <measurement group_id="O2" value="5.9" spread="1.3"/>
                    <measurement group_id="O3" value="6.3" spread="1.8"/>
                    <measurement group_id="O4" value="6.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Investigate the Efficacy on Sleep Onsel Latency of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log, Actigraphy and Psychological Tests.</title>
        <description>Actigraphy, sleep onset latency (SOL). An actigraph is a wrist-worn movement sensor that objectively record motor activity. Participants used an event button to mark bed time and rise time. The actiwatch is waterproof and participants were instructed not to take it off at any time during the data collection peroid.</description>
        <time_frame>1 day after 2-week treatment ended</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination</title>
            <description>Bright light + melatonin
Melatonin: Capsules, 3 mg, once every night
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
          </group>
          <group group_id="O2">
            <title>Melatonin</title>
            <description>Melatonin + placebo light
Melatonin: Capsules, 3 mg, once every night
placebo light therapy: Placebo light</description>
          </group>
          <group group_id="O3">
            <title>Bright Light</title>
            <description>Bright light + placebo capsule
Placebo melatonin: Capsule 3 mg, rice flour
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo capsule + placebo light
Placebo melatonin: Capsule 3 mg, rice flour
placebo light therapy: Placebo light</description>
          </group>
        </group_list>
        <measure>
          <title>To Investigate the Efficacy on Sleep Onsel Latency of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log, Actigraphy and Psychological Tests.</title>
          <description>Actigraphy, sleep onset latency (SOL). An actigraph is a wrist-worn movement sensor that objectively record motor activity. Participants used an event button to mark bed time and rise time. The actiwatch is waterproof and participants were instructed not to take it off at any time during the data collection peroid.</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="8"/>
                    <measurement group_id="O2" value="21" spread="19"/>
                    <measurement group_id="O3" value="15" spread="10"/>
                    <measurement group_id="O4" value="24" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Combination</title>
          <description>Melatonin: Capsules, 3 mg, once every night
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
        </group>
        <group group_id="E2">
          <title>Melatonin</title>
          <description>Melatonin: Capsules, 3 mg, once every night
placebo light therapy: Placebo light</description>
        </group>
        <group group_id="E3">
          <title>Bright Light</title>
          <description>Placebo melatonin: Capsule 3 mg, rice flour
Light therapy: Light therapy 10.000 lux by Miljølys AS</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo melatonin + placebo light therapy
Placebo melatonin: Capsule 3 mg, rice flour
placebo light therapy: Placebo light</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort in eyes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bjørn Bjorvatn</name_or_title>
      <organization>University of Bergen</organization>
      <phone>55586130</phone>
      <email>bjorn.bjorvatn@igs.uib.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

